Indeed, heterogeneous IFIT3 expression was observed in 16.4% of tumor specimens and no survival benefit for patients with tumors that expressed low IFIT3 levels was reported, with heterogeneity considered one of the potential explanations of divergent results. Here, IFIT3 is linked to neoplasm.